- Home
- XIFR vs GYRE Comparison
XIFR vs GYRE Comparison
Compare XIFR & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XIFR
- GYRE
- Stock Information
- Founded
- XIFR 2014
- GYRE 2002
- Country
- XIFR United States
- GYRE United States
- Employees
- XIFR N/A
- GYRE N/A
- Industry
- XIFR
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- XIFR
- GYRE Health Care
- Exchange
- XIFR NYSE
- GYRE Nasdaq
- Market Cap
- XIFR 874.5M
- GYRE 990.4M
- IPO Year
- XIFR N/A
- GYRE N/A
- Fundamental
- Price
- XIFR $8.85
- GYRE $8.88
- Analyst Decision
- XIFR Sell
- GYRE
- Analyst Count
- XIFR 2
- GYRE 0
- Target Price
- XIFR $6.00
- GYRE N/A
- AVG Volume (30 Days)
- XIFR 2.1M
- GYRE 209.4K
- Earning Date
- XIFR 04-29-2025
- GYRE 05-19-2025
- Dividend Yield
- XIFR 30.72%
- GYRE N/A
- EPS Growth
- XIFR N/A
- GYRE N/A
- EPS
- XIFR N/A
- GYRE 0.05
- Revenue
- XIFR $1,230,000,000.00
- GYRE $105,757,000.00
- Revenue This Year
- XIFR $13.82
- GYRE $22.01
- Revenue Next Year
- XIFR $0.21
- GYRE $88.14
- P/E Ratio
- XIFR N/A
- GYRE $184.70
- Revenue Growth
- XIFR 14.10
- GYRE N/A
- 52 Week Low
- XIFR $7.53
- GYRE $6.11
- 52 Week High
- XIFR $35.15
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- XIFR N/A
- GYRE 51.54
- Support Level
- XIFR N/A
- GYRE $7.03
- Resistance Level
- XIFR N/A
- GYRE $8.44
- Average True Range (ATR)
- XIFR 0.00
- GYRE 1.12
- MACD
- XIFR 0.00
- GYRE 0.23
- Stochastic Oscillator
- XIFR 0.00
- GYRE 92.33
About XIFR XPLR INFRASTRUCTURE LP
NextEra Energy Partners LP is formed to acquire, manage, and own contracted clean energy projects. It owns interests in wind and solar projects in North America, as well as natural gas infrastructure assets in Texas. Renewable energy assets consist of wind, solar, and solar-plus-storage projects and a stand-alone battery storage project, as well as contracted natural gas pipeline assets. Renewable energy sales generate maximum revenue for the company.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.